Company news

Transcenta Holding Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Notification letter and request form to non-registered holders

October 30, 2026

Notification letter and reply form to registered holders

October 30, 2026

Form of proxy for the extraordinary general meeting to be held on Thursday, November 19, 2026

October 30, 2026

Notice of extraordinary general meeting

October 30, 2026

(1) Proposed refreshment of scheme mandate limit and service provider sublimit and (2) notice of extraordinary general meeting

October 30, 2026

Update on measures and actions taken in resolving the disclaimer of opinion in the annual report for the year ended December 31, 2025

October 27, 2026

Voluntary announcement-receipt of the first payment in relation to the disposal of cdmo assets

October 20, 2026

Voluntary announcement-business update on the grant of China invention patents related to osemitamab (TST001) and its companion diagnostic antibody

October 11, 2026

Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026

October 7, 2026

Cancellation and grant of award pursuant to the share incentive scheme

September 30, 2026

Notification letter and request form to non-registered holders

September 15, 2026

Notification letter and reply form to registered holders

September 15, 2026

2026 Interim report

September 15, 2026

Transcenta Therapeutics Presents New Data for its Novel LIV1-Targeting ADC TST013 Demonstrating Potent Anti-Tumor Activity in PDX Models of Prostate Cancer and ER Positive /HER2 Negative Breast Cancer

April 23, 2026

Transcenta Therapeutics Appoints Dr. Christopher Hwang as Head of Global Partnerships for HiCB Platform

March 30, 2026

Transcenta Therapeutics to Present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference

February 24, 2026

Transcenta Therapeutics Announces Strategic Collaboration and Non-exclusive Licensing Agreement to Advance Integrated Continuous Biomanufacturing and Expand Global Access to Affordable Biologics

December 27, 2025

Transcenta Therapeutics Presents Updated Efficacy Data from the Phase I/II Transtar102 Trial of Osemitamab plus Nivolumab and CAPOX in First-Line G/GEJ Cancer at ESMO Asia

December 4, 2025

Transcenta Holding Limited (6628.HK) to Hold 2023 ASCO Business Update call Conference.

June 2, 2023

Transcenta Holding Limited (6628.HK) to Hold 2022 Annual Results Release Conference Call

March 20, 2023

Transcenta to Hold 3 Exchange Sessions on Post-SITC Business Update Call & TST003 data release and pipeline development progress update

November 9, 2022

Transcenta to Present Two Scientific Posters at SITC 2022 Annual Meeting

October 12, 2022

Decks

The 5 newest of 11 decks. Every deck is listed under its year.